CBIS LATEST NEWS.

2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009


CBIS NORTH AMERICAN ECONOMIC DEVELOPMENT INITIATIVE.


Cannabis Science's North American Economic Development Initiative has successfully launched with The Native American Agriculture Initiative Plan; 2017 CBIS/FSO NAC MBS. Together with Free Spirt Organics Native American Corporation, HRM Farms, Raymond C. Dabney University (RCDU), and American States University’s (ASU) Department of Agriculture, Cannabis Science has initiated a 250-Acre Industrial Hemp Project that allows for an all-inclusive Economic Development Plan in San Joaquin County. ASU and RCDU provide affordable and flexible education to the Native American community, and the city of Stockton. These Universities specialize in entrepreneurial and agricultural programs and offer scholarship opportunities. A key area of this economic development plan is job creation, and CBIS has provided many jobs to the community from the University site creation and Hemp Farm cultivation. Furthermore, vertical integration allows for jobs to be provided through the development of local industrial hemp industry, healthcare infrastructure, water management, waste management, technology, communications, and housing. CBIS and its partners intend to pass on any business opportunities related to hemp cultivation research and development to the citizens of San Joaquin County.

EDUCATION


Raymond C. Dabney University LogoRCDU is a compliment to a California online university that provides live seminars and workshops presented by a dedicated and experienced faculty of law professors. They offer general educational development designed to take you to the forefront of your profession. The curriculum delivers foundational knowledge and real-world skills to immediately prepare their students for their career. RCDU provides the financial and managerial resources needed for a non-traditional education, in the fields of law, business, and healthcare.

American States University LogoASU offers a combined thirty-seven state-approved certification and degree programs housed within five departments. Its primary purpose is to provide professional training in agricultural hemp research and development for pharmaceutical drugs targeting critical ailments such as Cancer, Epilepsy, Chronic Pain, Parkinson's Disease, Arthritis, PTSD, HIV/AIDs and other industries such as Alternate Biofuels, Construction, and Clothing and Automobile Materials. American States University has 5 main Education Initiatives:

 

PROVIDING HYBRID FOCUSED INTERACTIVE TRAINING

Online, in class, and in the field training gives our students the flexibility and hands-on education to learn their trade.

EMPHASIZING PRACTICAL ENTREPRENEURIAL EDUCATION

Students leave American States University with skills to create jobs in the community, not just look for jobs.

OFFERING AFFORDABLE AND EASY ACCESS TO EDUCATION

ASU's unique hybrid education model allows for courses at a low priced rate. Scholarships and subsidized packages are available to qualifying students.

TARGETING DISTRESSED COMMUNITIES

Affordable and entrepreneurial education means ASU can help struggling communities build themselves up.

SPECIALIZING IN R&D OF INDUSTRIAL HEMP

This is a massive, growing, and untapped industry that will directly benefit its participants through job creation and revenue streams.

JOB CREATION



Vertical integration allows Cannabis Science to provide many jobs throughout the community in agriculture, education, healthcare training, construction, and general retail services:

  • Job creation due to Universities and site services including laboratory facilities for research & development
  • Job creation due to students graduating from Universities with entrepreneurial skills to create their own jobs
  • Academic and vocational training, covering each applied industry;
  • Agricultural research
  • Development of industrial hemp industry
  • Development of healthcare infrastructure, including hospitals and health centers
  • Pharmaceutical and Alternative Medicines development
  • Creation of a sustainable, food security system that is based on sound agricultural practices that produce sufficient food for consumption and that are designed to reduce poverty and allow for real farm-to-table programs
  • Development of water management systems
  • Development of waste management systems that reduce the prevalence of critical risk factors for infectious diseases
  • Investment in communications infrastructure, to include satellite, internet, mechanical device development, and cell phone infrastructure; and
  • Support for policy, regulatory, and jurisdictional environments, as they pertain to public healthcare, agriculture, education, job creation, and most important; on the job training oriented for success
  • And other other key fundamentals depending on the demographics such as housing, apartments, dormitories, and retail services; restaurants, gas stations, grocery stores, clinics, pharmacies, and retail strip malls.

DRUG DEVELOPMENT


Cannabis Science is in partnership with ASU, Free Spirit Organics Native American Corporation, HRM Farms, AECG and RCDU to conduct a Native American Agriculture Initiative Plan; 2017 CBIS/FSO NAC MBS. This plan focuses on cannabinoid drug development using proven extraction methodologies derived from the Industrial Hemp plant, targeting critical ailments such as Cancer, PTSD, Chronic Pain, Arthritis, Parkinson’s Disease, Epilepsy, Autism, and HIV/AIDS. Cannabis Science has three main steps to execute the cannabinoid drug development:

  1. Define the effectiveness and specificity of cannabinoids.
  2. Identify and test drug delivery mechanisms.
  3. Test and evaluate the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in randomized controlled trials.

From here, 3 target markets will be sought after:

  1. FDA – Dr. written prescriptions for target critical ailments.
  2. Over the counter – Nutraceutical and cosmeceuticals.
  3. State by State Initiatives – Regulation, cultivation, laboratory, manufacturing, and distribution.

It is estimated that there will be $450 million US Hemp based CBD product sales in 2020, with 40% of that being pharmaceuticals. The creation of cannabinoid drugs will benefit those twofold; by bringing a financial increase to the parties and communities involved, and by increasing the overall social well-being of the community.

Cannabis Science Enthused With CNN Monitoring The Outcome Of The National State By State Voting To Legalize Medical Cannabis

COLORADO SPRINGS, Colo., Nov. 5, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is closely monitoring the CNN reporting of the outcome of the State by State voting to legalize medical cannabis. Target States in this voting session are Washington DC, Florida, Oregon, and Alaska.

Please visit:    http://www.cnn.com/2014/11/04/politics/marijuana-2014

The Company believes the Washington DC, approval is the most significant. Being the center of our federal political influential movements, it plays a key role influencing medical cannabis state-by-state initiatives as well as Federal laws governing the medical research on this plant.

Please visit:    http://money.cnn.com/2014/10/29/news/economy/legal-pot-vote

Currently, 23 states and the District of Columbia have passed laws allowing some degree of medical use of cannabis. With this as the backdrop, the Company believes this could lead to further acceptance and improvement of regulatory environment around medical cannabis in the United States and around the World, continuing with the domino effect that will benefit patients who have to rely on medical marihuana and deserve to receive quality assured medication in the context of the general healthcare.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

CANNABIS SCIENCE TEAM.



IN LOVING MEMORIAL.


"The CBIS family is shocked and saddened with the passing of Mario, Allen, and Ron. These distinguished gentlemen will leave voids in our Company, in our hearts, and in their communities that will never be filled in the same way. However, we will honor their legacies by continuing the great work they both contributed to and championed. Fortunately, these leaders helped position our Company for success and we will march forward in the direction they so aptly agreed, pointed, and marched with us in. With our talented executive management team, our expert consultants, our Corporate Advisory Board Members, and all of our loyal shareholders, we will succeed."

- Mr. Raymond C. Dabney; President, C.E.O. and Co-founder


Dr. Allen A. Herman

Dr. Allen A. Herman

- Chief Medical Officer & President of the Scientific Advisory Board


Dr. Herman was CBIS' Chief Medical Officer (CMO) and served as the President of the Company's Scientific Advisory Board and Member of the International Government Affairs Board. In this capacity and with his broad medical knowledge base, Dr. Herman was able to help shape and direct the Company's successful research and development initiatives, including the structuring of partnerships with several well-established specialized research institutions, local and international universities, and government agencies. Along with Mr. Dabney, Dr. Herman led a formidable medical team to create the Cannabis Science Global Consortium, a research and development framework and platform to cooperate and collaborate with stakeholders worldwide. The Consortium links universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms.


Honorable Ronald V. Dellums

Honorable Ronald V. Dellums

- President of International Government Affairs Board


Mr. Dellums served as the President of CBIS’ International Government Affairs Board and was a member of the Company’s Scientific Advisory Board. In this capacity, Mr. Dellums helped develop the Company’s relationships with public and private sector stakeholders worldwide. A life-long advocate of peace and social justice, Ron Dellums served for 27 years as an outspoken and highly respected member of the US House of Representatives. Initially seeking a life in education, community activism and social work, Mr. Dellums was called to public office in 1967. His tenure in politics has been defined by a strong adherence to the principles of social justice, community activism and peace as viable and necessary national and international pursuits.


Mario Lap

Mario Lap

- Director & President of European Operations


Mr. Lap was the President of CBIS European Operations and a CBIS Director. He brought the Company a unique combination of expertise in Dutch and greater European medical cannabis law and policy as well as in the areas of health care, IT security, law enforcement, and government relations. Mr. Lap, last served as a Dutch health and IT regulatory lawyer in Amsterdam, had an extensive educational background through studies at the Het Amsterdams Lyceum, Colloqium Doctum University of Amsterdam, University of Amsterdam Law School, Open University and University of Liverpool, and speaks fluent Dutch, English, French, and German. With this he was able to make strong public presence through his numerous international papers and legislative initiatives regarding medical and non-medicinal cannabis laws and access throughout Europe. He also made several television and radio appearances on CNN, BBC, France 2, RTL, and various Dutch public and commercial channels to give public education and information on policy, laws, and current medical breakthroughs.


CBIS BOTTLE IT.


CBIS Bottle It is Southern California’s premier manufacturer of polyethylene terephthalate (PET) bottles and containers. CBIS Bottle It supplies preform and PET bottles to customers throughout North America and Internationally seeking both unique and stock bottling product options. Established in 2014, CBIS Bottle It manufactures various preforms for various bottled waters, energy drinks and vitamin shots, tinctures, drops, various pill bottles, sprays, and various food containers for rice, flour, milk, dry food mixes, spices, mixed nuts, cookies, and the list goes on. CBIS Bottle It is a PET injection-mold and blow-mold manufacturer servicing the food and beverage industry that has reported approximately $1,500,00.00 in revenues each year for 2016 and 2017 consecutively. PET containers are the perfect solution for a business as the material itself is hard, durable, tough, light weight, inexpensive, and reusable. Our strategic location in the inland empire allows us to serve California and the surrounding areas with pristine efficiency.